Home / Healthcare/ Sanofi agrees to buy US peer Bioverativ for $11.6 b

Sanofi agrees to buy US peer Bioverativ for $11.6 b


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 24 January 2018 00:02


FILE PHOTO: A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris REUTERS/Christian Hartmann

 

PARIS (Reuters): French healthcare group Sanofi has agreed to buy US peer Bioverativ for $11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases.

Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 per share in cash, marking a premium of 64 percent to Bioverativ’s closing price on January 19, 2018.

Bioverativ, a hemophilia drug maker, was separated from Biogen Inc early last year.

The Bioverativ deal also comes after Sanofi had failed to land major takeovers in recent years.

Sanofi lost out on buying California-based cancer specialist Medivation to Pfizer in 2016, and missed out on Swiss biotech company Actelion, which was bought by Johnson & Johnson last year.

“With Bioverativ, a leader in the growing hemophilia market, Sanofi enhances its presence in specialty care and leadership in rare diseases, in line with its 2020 Roadmap, and creates a platform for growth in other rare blood disorders,” said Sanofi chief executive Olivier Brandicourt, in a statement.

“Together, we have a great opportunity to bring innovative medicines to patients worldwide, building on Bioverativ’s success in driving new standards of care with its extended half-life factor replacement therapies,” he added.

Sanofi expects the acquisition to be immediately accretive to its business earnings per share in the 2018 full financial year and up to 5 percent accretive for the following year.

Sanofi is also projected to achieve a return on its invested capital (ROIC) in excess of the cost of capital within three years, while the French group also expects to preserve its strong credit rating, Sanofi added.

 


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Gota’s Viyathmaga and a Government at a standstill

Monday, 28 May 2018

American economist and social theorist Thomas Sowell once said, “The big divide in this country is not between Democrats and Republicans, or men and women, but between talkers and doers.”


Designers of Sri Lanka’s Future: Episode 3 Channa de Silva: ‘Technology should be for people’s conve

Monday, 28 May 2018

Channa de Silva, CEO of LankaClear, Sri Lanka’s official clearing and payment services provider, declares convincingly: “I firmly believe that technology should be for improving people’s convenience.”


Wonder Woman

Saturday, 26 May 2018

Tell me about yourself – what you do, your family, your career and so on


Separatist threat arising from indifference to environmental concerns

Saturday, 26 May 2018

The 100-day agitation against a major copper smelting plant at Thoothukudi in Tamil Nadu, which led to 13 deaths in police firing earlier this week, has brought into the open the many-faceted dangers of ignoring environmental issues.


Columnists More